Loading…
Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine
Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study w...
Saved in:
Published in: | Medical laboratory journal 2022-11, Vol.16 (6), p.40-44 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 44 |
container_issue | 6 |
container_start_page | 40 |
container_title | Medical laboratory journal |
container_volume | 16 |
creator | Muragendraswami Astagimath Suman Doddamani Vishwanath Patil Raviraja Aryapu |
description | Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study was performed to compare the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) responses after first and second dose of coronavirus disease 2019 (COVID-19) vaccination. Methods: This cross-sectional study included 60 people who were vaccinated with the AstraZeneca vaccine at Karnataka Institute of Medical Sciences, Hubballi, India. The subjects were divided into two groups. Group I included 30 people who had received a single dose of the vaccine, and group II included 30 people who had received two doses of the vaccine. Exclusion criteria included having a history of influenza like illness/severe acute respiratory infection/proven COVID-19 infection in past 6 months. The antibody response was measured by the Anti-SARS-CoV-2 IgG test using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack. Results: We observed that 97% of the subjects had reactive IgG antibodies after receiving two doses of the vaccine, whereas only 83% of the subjects developed antibodies after a single dose of the vaccine. A positive correlation was observed between the development of reactive antibodies and the duration between the first dose and the second dose (r=0.24). Conclusion: Based on the results, the two-dose vaccination with the AstraZeneca vaccine is beneficial over the single-dose vaccination for protection against COVID-19. Moreover, increasing the duration between doses might improve the antibody response. |
format | article |
fullrecord | <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1ca127a8b78a42b88d61caf51c6a8595</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1ca127a8b78a42b88d61caf51c6a8595</doaj_id><sourcerecordid>oai_doaj_org_article_1ca127a8b78a42b88d61caf51c6a8595</sourcerecordid><originalsourceid>FETCH-doaj_primary_oai_doaj_org_article_1ca127a8b78a42b88d61caf51c6a85953</originalsourceid><addsrcrecordid>eNqtjNEKgjAUQPdQUJT_sB8YuDl1PoZlCUGQ4eu4zhkTc7L50t8n0Sf0dOAcOCu0ZXEkCOc826DA-z4MQxpxRtNsi66HcTakOtwrktuaMFw-z_iu_WRHrzF0s3a4MM7PGMYWV1rZBUe7NNvh_FaXR0IzXINSZtR7tO5g8Dr4cYfK4vTIL6S10MvJmRe4t7Rg5FdY95TgZqMGLakCylIQTSqAs0aINllUF1OVgIizOPrn6wNt2VQo</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine</title><source>EZB Electronic Journals Library</source><creator>Muragendraswami Astagimath ; Suman Doddamani ; Vishwanath Patil ; Raviraja Aryapu</creator><creatorcontrib>Muragendraswami Astagimath ; Suman Doddamani ; Vishwanath Patil ; Raviraja Aryapu</creatorcontrib><description>Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study was performed to compare the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) responses after first and second dose of coronavirus disease 2019 (COVID-19) vaccination. Methods: This cross-sectional study included 60 people who were vaccinated with the AstraZeneca vaccine at Karnataka Institute of Medical Sciences, Hubballi, India. The subjects were divided into two groups. Group I included 30 people who had received a single dose of the vaccine, and group II included 30 people who had received two doses of the vaccine. Exclusion criteria included having a history of influenza like illness/severe acute respiratory infection/proven COVID-19 infection in past 6 months. The antibody response was measured by the Anti-SARS-CoV-2 IgG test using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack. Results: We observed that 97% of the subjects had reactive IgG antibodies after receiving two doses of the vaccine, whereas only 83% of the subjects developed antibodies after a single dose of the vaccine. A positive correlation was observed between the development of reactive antibodies and the duration between the first dose and the second dose (r=0.24). Conclusion: Based on the results, the two-dose vaccination with the AstraZeneca vaccine is beneficial over the single-dose vaccination for protection against COVID-19. Moreover, increasing the duration between doses might improve the antibody response.</description><identifier>ISSN: 2538-4449</identifier><language>eng</language><publisher>Golestan University of Medical Sciences</publisher><subject>covid-19 ; covid-19 vaccines ; pandemics</subject><ispartof>Medical laboratory journal, 2022-11, Vol.16 (6), p.40-44</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Muragendraswami Astagimath</creatorcontrib><creatorcontrib>Suman Doddamani</creatorcontrib><creatorcontrib>Vishwanath Patil</creatorcontrib><creatorcontrib>Raviraja Aryapu</creatorcontrib><title>Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine</title><title>Medical laboratory journal</title><description>Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study was performed to compare the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) responses after first and second dose of coronavirus disease 2019 (COVID-19) vaccination. Methods: This cross-sectional study included 60 people who were vaccinated with the AstraZeneca vaccine at Karnataka Institute of Medical Sciences, Hubballi, India. The subjects were divided into two groups. Group I included 30 people who had received a single dose of the vaccine, and group II included 30 people who had received two doses of the vaccine. Exclusion criteria included having a history of influenza like illness/severe acute respiratory infection/proven COVID-19 infection in past 6 months. The antibody response was measured by the Anti-SARS-CoV-2 IgG test using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack. Results: We observed that 97% of the subjects had reactive IgG antibodies after receiving two doses of the vaccine, whereas only 83% of the subjects developed antibodies after a single dose of the vaccine. A positive correlation was observed between the development of reactive antibodies and the duration between the first dose and the second dose (r=0.24). Conclusion: Based on the results, the two-dose vaccination with the AstraZeneca vaccine is beneficial over the single-dose vaccination for protection against COVID-19. Moreover, increasing the duration between doses might improve the antibody response.</description><subject>covid-19</subject><subject>covid-19 vaccines</subject><subject>pandemics</subject><issn>2538-4449</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqtjNEKgjAUQPdQUJT_sB8YuDl1PoZlCUGQ4eu4zhkTc7L50t8n0Sf0dOAcOCu0ZXEkCOc826DA-z4MQxpxRtNsi66HcTakOtwrktuaMFw-z_iu_WRHrzF0s3a4MM7PGMYWV1rZBUe7NNvh_FaXR0IzXINSZtR7tO5g8Dr4cYfK4vTIL6S10MvJmRe4t7Rg5FdY95TgZqMGLakCylIQTSqAs0aINllUF1OVgIizOPrn6wNt2VQo</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Muragendraswami Astagimath</creator><creator>Suman Doddamani</creator><creator>Vishwanath Patil</creator><creator>Raviraja Aryapu</creator><general>Golestan University of Medical Sciences</general><scope>DOA</scope></search><sort><creationdate>20221101</creationdate><title>Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine</title><author>Muragendraswami Astagimath ; Suman Doddamani ; Vishwanath Patil ; Raviraja Aryapu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-doaj_primary_oai_doaj_org_article_1ca127a8b78a42b88d61caf51c6a85953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>covid-19</topic><topic>covid-19 vaccines</topic><topic>pandemics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muragendraswami Astagimath</creatorcontrib><creatorcontrib>Suman Doddamani</creatorcontrib><creatorcontrib>Vishwanath Patil</creatorcontrib><creatorcontrib>Raviraja Aryapu</creatorcontrib><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Medical laboratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muragendraswami Astagimath</au><au>Suman Doddamani</au><au>Vishwanath Patil</au><au>Raviraja Aryapu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine</atitle><jtitle>Medical laboratory journal</jtitle><date>2022-11-01</date><risdate>2022</risdate><volume>16</volume><issue>6</issue><spage>40</spage><epage>44</epage><pages>40-44</pages><issn>2538-4449</issn><abstract>Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study was performed to compare the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) responses after first and second dose of coronavirus disease 2019 (COVID-19) vaccination. Methods: This cross-sectional study included 60 people who were vaccinated with the AstraZeneca vaccine at Karnataka Institute of Medical Sciences, Hubballi, India. The subjects were divided into two groups. Group I included 30 people who had received a single dose of the vaccine, and group II included 30 people who had received two doses of the vaccine. Exclusion criteria included having a history of influenza like illness/severe acute respiratory infection/proven COVID-19 infection in past 6 months. The antibody response was measured by the Anti-SARS-CoV-2 IgG test using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack. Results: We observed that 97% of the subjects had reactive IgG antibodies after receiving two doses of the vaccine, whereas only 83% of the subjects developed antibodies after a single dose of the vaccine. A positive correlation was observed between the development of reactive antibodies and the duration between the first dose and the second dose (r=0.24). Conclusion: Based on the results, the two-dose vaccination with the AstraZeneca vaccine is beneficial over the single-dose vaccination for protection against COVID-19. Moreover, increasing the duration between doses might improve the antibody response.</abstract><pub>Golestan University of Medical Sciences</pub><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2538-4449 |
ispartof | Medical laboratory journal, 2022-11, Vol.16 (6), p.40-44 |
issn | 2538-4449 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_1ca127a8b78a42b88d61caf51c6a8595 |
source | EZB Electronic Journals Library |
subjects | covid-19 covid-19 vaccines pandemics |
title | Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A00%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-SARS-CoV-2%20IgG%20Response%20after%20First%20and%20Second%20Dose%20of%20COVID-19%20Vaccine&rft.jtitle=Medical%20laboratory%20journal&rft.au=Muragendraswami%20Astagimath&rft.date=2022-11-01&rft.volume=16&rft.issue=6&rft.spage=40&rft.epage=44&rft.pages=40-44&rft.issn=2538-4449&rft_id=info:doi/&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_1ca127a8b78a42b88d61caf51c6a8595%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-doaj_primary_oai_doaj_org_article_1ca127a8b78a42b88d61caf51c6a85953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |